ProMIS Neurosciences has appointed Ivana Rubino, Ph.D., as chief commercial officer to lead market access, payer strategy and launch readiness for PMN310, a humanized monoclonal antibody engineered to bind toxic amyloid-beta oligomers while sparing monomers and deposited plaque. The candidate is in the PRECISE-AD Phase 1b study, with unblinded 12-month topline data expected in the first quarter of 2027. The selectivity profile is intended to separate therapeutic effect from the off-target binding associated with earlier amyloid-directed antibodies.
Key Points
- PMN310 targets toxic amyloid-beta oligomers, not monomers or plaque
- Phase 1b PRECISE-AD topline data expected first quarter 2027
- Commercial leadership hired to build payer and launch infrastructure
Longevity Analysis
Amyloid-directed therapy has been limited less by potency than by precision; antibodies that bind plaque and monomer alongside the soluble oligomeric species have carried vascular inflammatory risk that constrains dosing. Narrowing recognition to the conformations most closely tied to synaptic injury is an attempt to let the immune machinery clear what is harmful without disturbing what is inert, preserving the cerebral vasculature that supplies the tissue being protected. For cognitive longevity, the practical value of such a candidate will depend on pairing it with earlier biomarker-based identification of risk, long before symptomatic decline makes clearance a late intervention.
Original published by LT Wire.